98%
921
2 minutes
20
Purpose: This randomized, controlled trial aimed to assess the sedative effects of esketamine and sufentanil combined with propofol during EUS.
Patients And Methods: Three hundred and forty patients undergone EUS were randomly divided into two groups to receive esketamine 0.25 mg/kg combined with propofol (esketamine group) or sufentanil 0.1 μg/kg combined with propofol (sufentanil group). The primary outcome measure was respiratory depression incidence. The secondary outcomes included the incidence of body movements, propofol dosage, lowest SPO during the operation, and management of airway obstruction. In addition, other procedures and anesthesia-related outcomes, and postoperative complications were recorded.
Results: A total of 340 patients underwent randomization. Of these, 172 were assigned to the esketamine group and 168 were assigned to the sufentanil group. 1 patient in the esketamine group was lost in the follow-up. During the EUS, 9 patients (5.3%) in the esketamine group and 26 (15.5%) in the sufentanil group developed respiratory depression; this difference was statistically significant ( = 0.002). Regarding secondary outcomes, the incidence of body movements, induction dosage, supplemental times, and total dosage of propofol were much higher in the sufentanil group than in the esketamine group ( < 0.05). In addition, the lowest SPO during the operation, occurrence rate of airway intervention, and management of airway obstruction were significantly different ( < 0.05). Compared to the sufentanil group, the induction time of sedation in the esketamine group was shorter, and the hemodynamics were more stable ( < 0.05). In addition, there were significant differences in the PACU incidence rates of nausea or vomiting between the two groups ( < 0.05), whereas the following day's complications showed no statistical difference.
Conclusion: Esketamine combined with propofol for sedation during EUS can decrease respiratory depression, reduce the dosage of propofol and PONV, and provide a more stable hemodynamic state. Consequently, esketamine could be considered as a potential alternative to sufentanil for sedation during EUS.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748005 | PMC |
http://dx.doi.org/10.2147/JPR.S498499 | DOI Listing |
J Perianesth Nurs
September 2025
Department of Anesthesiology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address:
Purpose: This study aimed to evaluate the effects of different doses of esketamine with etomidate on anesthesia and postoperative cognitive function of elderly patients undergoing painless tracheoscopy.
Design: This was a double-blind, randomized controlled trial.
Methods: In this study, 150 patients over 65 were divided into group A (low-dose: 0.
J Cancer Res Ther
September 2025
Department of Anesthesiology, Cardiovascular Institute, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Background: This study evaluated the efficacy and safety of esketamine plus dexmedetomidine for sedation and analgesia during computed tomography (CT)-guided lung tumor percutaneous microwave ablation (MWA).
Methods: Patients undergoing CT-guided percutaneous MWA of lung tumors were randomly divided into two groups: esketamine plus dexmedetomidine (Group E) and sufentanil plus dexmedetomidine (Group S). The patients' general information, mean arterial pressure (MAP), heart rate (HR), peripheral oxygen saturation, respiratory rate (RR), partial pressure of end-tidal carbon dioxide, bispectral index, and Ramsay sedation score were recorded before anesthesia administration (T0), after dexmedetomidine loading dose (T1), during percutaneous puncture (T2), during ablation (T3), at the end of surgery (T4), and during recovery of consciousness (T5).
Mol Psychiatry
August 2025
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Esketamine, commonly used to treat treatment-resistant depression, has pharmacological mechanisms that remain incompletely understood. Brain organoids offer a human-relevant platform for investigating the cellular and molecular effects of drugs. In this study, we investigated the effects of esketamine on the electrophysiology and metabolism of brain organoids derived from iPSCs of healthy control subjects and depressed patients.
View Article and Find Full Text PDFBMC Pharmacol Toxicol
August 2025
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Aims: This study aims to investigate the safety profile of Esketamine, with a particular focus on comparing adverse events (AEs) between adults (< 65 years) and older adults (≥ 65 years) using data from the FDA Adverse Event Reporting System (FAERS).
Methods: We conducted a comprehensive analysis of FAERS data from 2019 to 2024, identifying 6,452 Esketamine-related AE reports. After removing data without age information, these reports were categorized into two age groups: 536 from older adults and 3,566 from younger adults.
J Pain Res
August 2025
Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Objective: This study aims to evaluate the efficacy of esketamine as an epidural adjuvant in mitigating postoperative pain, particularly following the discontinuation of epidural analgesia in patients undergoing open surgery for gynecological malignancies.
Design: A randomized controlled trial.
Methods: Eighty-eight patients were randomized to receive either esketamine (0.